EdgarLookup

NEXTNAV INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that NEXTNAV INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-4138.5%
Profit Margin
Net income ÷ revenue
-76.6%
Return on Assets
Net income ÷ assets
-3.86x
Debt-to-Equity
Total liabilities ÷ equity
-19.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.57M Mar 17, 2026
FY2025 Dec 31, 2024 $5.67M Mar 17, 2026
FY2024 Dec 31, 2023 $3.86M Mar 12, 2025
FY2023 Dec 31, 2022 $3.93M Mar 13, 2024
FY2022 Dec 31, 2021 $763.0K Mar 30, 2023
FY2021 Dec 31, 2020 $569.0K Mar 23, 2022

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($189.25M) Mar 17, 2026
FY2025 Dec 31, 2024 ($101.88M) Mar 17, 2026
FY2024 Dec 31, 2023 ($71.74M) Mar 12, 2025
FY2023 Dec 31, 2022 ($40.12M) Mar 13, 2024
FY2022 Dec 31, 2021 ($144.67M) Mar 30, 2023
FY2021 Dec 31, 2020 ($137.34M) Mar 23, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($70.23M) Mar 17, 2026
FY2025 Dec 31, 2024 ($60.10M) Mar 17, 2026
FY2024 Dec 31, 2023 ($63.53M) Mar 12, 2025
FY2023 Dec 31, 2022 ($65.54M) Mar 13, 2024
FY2022 Dec 31, 2021 ($42.43M) Mar 30, 2023
FY2021 Dec 31, 2020 ($29.47M) Mar 23, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $18.95M Mar 17, 2026
FY2025 Dec 31, 2024 $16.24M Mar 17, 2026
FY2024 Dec 31, 2023 $19.50M Mar 12, 2025
FY2023 Dec 31, 2022 $17.06M Mar 13, 2024
FY2022 Dec 31, 2021 $9.47M Mar 30, 2023
FY2021 Dec 31, 2020 $8.78M Mar 23, 2022

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $39.56M Mar 17, 2026
FY2025 Dec 31, 2024 $33.51M Mar 17, 2026
FY2024 Dec 31, 2023 $30.32M Mar 12, 2025
FY2023 Dec 31, 2022 $36.93M Mar 13, 2024
FY2022 Dec 31, 2021 $13.56M Mar 30, 2023
FY2021 Dec 31, 2020 $13.26M Mar 23, 2022

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($50.75M) Mar 17, 2026
FY2025 Dec 31, 2024 ($38.01M) Mar 17, 2026
FY2024 Dec 31, 2023 ($35.44M) Mar 12, 2025
FY2023 Dec 31, 2022 ($37.10M) Mar 13, 2024
FY2022 Dec 31, 2021 ($47.93M) Mar 30, 2023
FY2021 Dec 31, 2020 ($28.41M) Mar 23, 2022

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $50.0K Mar 17, 2026
FY2025 Dec 31, 2024 $350.0K Mar 17, 2026
FY2024 Dec 31, 2023 $2.75M Mar 12, 2025
FY2023 Dec 31, 2022 $2.96M Mar 13, 2024
FY2022 Dec 31, 2021 $1.02M Mar 30, 2023
FY2021 Dec 31, 2020 $6.42M Mar 23, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $247.02M Mar 17, 2026
FY2025 Dec 31, 2024 $161.74M Mar 17, 2026
FY2024 Dec 31, 2023 $162.16M Mar 12, 2025
FY2023 Dec 31, 2022 $123.79M Mar 13, 2024
FY2022 Dec 31, 2021 $136.82M Mar 30, 2023
FY2021 Dec 31, 2020 $44.90M Mar 23, 2022

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $333.25M Mar 17, 2026
FY2025 Dec 31, 2024 $111.62M Mar 17, 2026
FY2024 Dec 31, 2023 $82.06M Mar 12, 2025
FY2023 Dec 31, 2022 $19.92M Mar 13, 2024
FY2022 Dec 31, 2021 $36.87M Mar 30, 2023
FY2021 Dec 31, 2020 $165.68M Mar 23, 2022

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($86.24M) Mar 17, 2026
FY2025 Dec 31, 2024 $50.12M Mar 17, 2026
FY2024 Dec 31, 2023 $78.73M Mar 12, 2025
FY2023 Dec 31, 2022 $100.02M Mar 13, 2024
FY2022 Dec 31, 2021 $99.96M Mar 30, 2023
FY2021 Dec 31, 2020 ($490.38M) Mar 23, 2022
FY2021 Dec 31, 2019 ($327.36M) Mar 23, 2022

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $19.16M Mar 17, 2026
FY2025 Dec 31, 2024 $16.97M Mar 17, 2026
FY2025 Dec 31, 2023 $17.98M Mar 17, 2026
FY2024 Dec 31, 2022 $17.49M Mar 12, 2025

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.05B) Mar 17, 2026
FY2025 Dec 31, 2024 ($862.11M) Mar 17, 2026
FY2024 Dec 31, 2023 ($760.23M) Mar 12, 2025
FY2023 Dec 31, 2022 ($688.49M) Mar 13, 2024
FY2022 Dec 31, 2021 ($647.86M) Mar 30, 2023
FY2021 Dec 31, 2020 ($490.28M) Mar 23, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Mar 17, 2026
FY2025 Dec 31, 2024 0 Mar 17, 2026
FY2024 Dec 31, 2023 0 Mar 12, 2025
FY2023 Dec 31, 2022 0 Mar 13, 2024
FY2022 Dec 31, 2021 (6) Mar 30, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Mar 17, 2026
FY2025 Dec 31, 2024 0 Mar 17, 2026
FY2024 Dec 31, 2023 0 Mar 12, 2025
FY2023 Dec 31, 2022 0 Mar 13, 2024
FY2022 Dec 31, 2021 (6) Mar 30, 2023

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 135.37M Mar 17, 2026
FY2025 Dec 31, 2024 131.14M Mar 17, 2026
FY2024 Dec 31, 2023 111.13M Mar 12, 2025
FY2023 Dec 31, 2022 106.42M Mar 13, 2024
FY2022 Dec 31, 2021 96.55M Mar 30, 2023
FY2021 Dec 31, 2020 7.35M Mar 23, 2022